ANTUREC's research has the aim to improve cancer outcome by therapy with new recombinant and targeted drugs.
The ANTUREC Pharmaceuticals team has made the following progress:
1. Manufacturer´s authorization for tTF-NGR renewed: 2021-05-17
2. Phase III study in patients with sarcomas approved by:
3. First patient on phase III study: 2021-11-12
ANTUREC's mission embraces research and development in the area of new targeted recombinant drugs against cancer and the translation of promising compounds from the laboratory to the clinic. ANTURECs first ANti TUmor RECombinant pharmaceutical – the fusion protein tTF-NGR – is in clinical phase II/III studies in oncology. In addition to the clinical lead structure tTF-NGR, ANTUREC follows active preclinical programs on other targeted proteins.
ANTUREC is a privately owned pharmaceutical company devoted to anticancer drug development. The company was founded in 2020 by Wolfgang E. Berdel, Christian Schwöppe, and Ari Bizimis.
ANTUREC's CEOs are Wolfgang E. Berdel and Ari Bizimis, Christian Schwöppe is CSO of the company. Below, you can find each CV as a PDF.
By targeting tissue factor to tumor vasculature we aim to selectively occlude tumor vessels and induce tumor infarction. Our target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. We have designed and studied truncated tissue factor (tTF) with a C- terminal GNGRAHA peptide (tTF-NGR) binding to CD13 and causing tumor vascular thrombosis with subsequent tumor infarction.
In our clinical studies we combine tTF-NGR with cytotoxic drugs. When tTF-NGR is given at the time of high intratumoral cytotoxic drug levels, the tumor vessels will be occluded resulting in tumor-entrapped drugs. By this mechanism, the antitumor activity of cyctotoxic drugs can be significantly enhanced. Vice versa, the activity of tTF-NGR is increased by the apoptotic action of the cytotoxic drugs on tumor cells and tumor endothelial cells through upregulation of phosphatidylserine. This principle is tested in a first randomized clinical study in soft tissue sarcoma.
As tTF-NGR targets the tumor vasculature, which is similar in different tumor types, the principle of entrapping tumor therapeutics by tTF-NGR induced vascular occlusion, if successful in the active trial, can be generalized as a treatment modality for multiple vascularized tumor entities.
This list includes preclinical studies, clinical phase I studies, information on "Good Manufacturing Practice" (GMP) guidelines and information on the tTF-NGR working group of the university hospital Muenster.
The list was last updated on Feb. 2, 2021.